Feature Aethlon readies U.S. study of the Hemopurifier By Len Zehr Aethlon Medical (OTCQB:AEMD), sporting FDA approval of an investigational drug exemption (IDE), plans to begin treating patients infected with hepatitis C virus (HCV) early next year in a feasibility study... October 1, 2013